TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.
Resource
J. Clin. Oncol., 33(15),
Journal
J. Clin. Oncol.
Journal Volume
33
Journal Issue
15
Pages
-
Date Issued
2015
Date
2015
Author(s)
Yang, James Chih-Hsin
Popat, Sanjay
Georgiou, Panos
Miyamoto, Emiko
Isaacson, Jeffrey D.
Wakelee, Heather A.
SDGs